v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Nov. 30, 2025
May 31, 2025
Dec. 31, 2024
May 31, 2024
Current assets:          
Cash and cash equivalents $ 3,452,891     $ 874,238  
Other receivables and prepayments 139,633     85,316  
Total current assets 3,592,524     959,554  
Long-term investments, net 15,098,846     15,098,846  
Long-term deposits     71,823  
Total Assets 18,691,370     16,130,223  
Property and equipment, net      
Current liabilities:          
Accounts payable and accrued expenses 1,071,715     918,611  
Operating lease liabilities, current 24,428     102,225  
Total current liabilities 4,593,823     4,338,980  
Operating lease liabilities, non-current       14,182  
Total Liabilities 4,899,823     4,353,162  
Commitments and contingencies      
TEMPORARY EQUITY          
Contingently redeemable warrants 47,000      
Total temporary equity 47,000      
EQUITY          
Additional paid-in capital 97,000,188     93,474,825  
Accumulated other comprehensive (loss) income (92,310)     89,162  
Accumulated deficit (73,792,798)     (72,429,528)  
Total stockholders’ deficit 23,115,160     21,134,514  
Non-controlling interests (9,370,613)     (9,357,453)  
Total equity 13,744,547     11,777,061  
Total Liabilities, Temporary Equity and Equity 18,691,370     16,130,223  
Related Party          
Current liabilities:          
Amounts due to related parties 79,180     79,644  
Convertible notes to a related party 3,418,500     3,238,500  
Convertible notes to a related party 306,000      
DiamiR Biosciences Corp          
Current assets:          
Cash and cash equivalents   $ 84,890 $ 56,836   $ 70,276
Accounts receivable   131,091   89,281
Other receivables and prepayments   5,704 46,649   120,139
Total current assets   221,685 103,485   279,696
Total Assets   481,065 384,624   579,833
Property and equipment, net   17,195 20,029   40,857
Right of use asset, net   44,424 63,349   61,519
Intangible assets   197,761 197,761   197,761
Current liabilities:          
Accounts payable and accrued expenses   673,396 231,858   148,648
Operating lease liabilities, current   38,442 41,383   40,178
Deferred revenue   43,982  
Total current liabilities   711,838 317,223   188,826
Commitments and contingencies      
EQUITY          
Preferred stock value    
Ordinary shares, value   4,441 4,441   4,441
Additional paid-in capital   4,741,863 4,729,169   4,670,165
Accumulated deficit   (6,232,526) (5,822,571)   (5,079,336)
Total stockholders’ deficit   (1,486,222) (1,088,961)   (404,730)
Total equity   (1,486,222) (1,088,961)   (404,730)
Total Liabilities, Temporary Equity and Equity   481,065 384,624   579,833
DiamiR Biosciences Corp | Related Party          
Current liabilities:          
Operating lease liabilities, non-current   3,324 22,698   22,036
Convertible notes to a related party   1,252,125 957,662   614,182
Income taxes payable   176,002   159,519
Total Liabilities   $ 1,967,287 $ 1,473,585   $ 984,563
Class A Ordinary Shares          
EQUITY          
Ordinary shares, value 62     37  
Class B Ordinary Shares          
EQUITY          
Ordinary shares, value $ 18     $ 18